Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Markets issued their FY2027 EPS estimates for Candel Therapeutics in a research report issued to clients and investors on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will earn ($1.52) per share for the year. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.29) per share.
Candel Therapeutics (NASDAQ:CADL - Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06.
A number of other equities analysts also recently issued reports on CADL. Canaccord Genuity Group cut their target price on Candel Therapeutics from $25.00 to $13.00 and set a "buy" rating for the company in a research note on Friday. Stifel Nicolaus decreased their price target on Candel Therapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday. Zacks Research downgraded Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Wednesday, October 14th. Bank of America raised Candel Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $12.00 to $18.00 in a report on Monday, September 21st. Finally, Jefferies Financial Group assumed coverage on Candel Therapeutics in a research report on Thursday, October 22nd. They issued a "buy" rating and a $25.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Candel Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $18.57.
Read Our Latest Research Report on CADL
Candel Therapeutics Stock Performance
NASDAQ CADL opened at $6.20 on Monday. The company has a current ratio of 7.57, a quick ratio of 7.57 and a debt-to-equity ratio of 0.37. The business's 50 day moving average is $9.75 and its two-hundred day moving average is $8.39. Candel Therapeutics has a 12-month low of $4.35 and a 12-month high of $14.00. The stock has a market capitalization of $474.42 million, a price-to-earnings ratio of -4.19 and a beta of -0.27.
Institutional Trading of Candel Therapeutics
A number of institutional investors have recently added to or reduced their stakes in CADL. BlackRock Inc. acquired a new position in Candel Therapeutics during the second quarter worth about $51,181,000. Bank of America Corp DE purchased a new position in Candel Therapeutics in the second quarter valued at about $2,873,000. Wellington Management Group LLP purchased a new position in Candel Therapeutics in the second quarter valued at about $2,119,000. Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at approximately $1,975,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Candel Therapeutics during the 1st quarter valued at approximately $845,000. Hedge funds and other institutional investors own 13.93% of the company's stock.
Latest Candel Therapeutics News
These are some of the CADL news items that stood out recently:
- Positive Sentiment: Candel reported a third-quarter loss of $0.28 per share, narrower than analysts’ expected loss of $0.34. Third-quarter results and corporate update
- Positive Sentiment: HC Wainwright, Canaccord Genuity and Stifel lowered their price targets but maintained Buy ratings, signaling continued analyst optimism despite the revised outlook.
- Negative Sentiment: Law firm Block & Leviton announced an investigation into whether Candel misled investors. The announcement describes an investigation, not a finding of wrongdoing. Securities investigation announcement
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.